PSNL Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -82.06%. Personalis, Inc.'s return on equity of -39.33% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Personalis, Inc. has a consensus price target of $11.14, signalling upside risk potential of 7.56%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 11.94%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Personalis, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Personalis, Inc..

Personalis, Inc. has a beta of 1.960, which suggesting that the stock is 96.049% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Personalis, Inc.'s net income of -$21.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 12.65x versus 13.79x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -735.19%. Personalis, Inc.'s return on equity of -39.33% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Personalis, Inc. has a consensus price target of $11.14, signalling upside risk potential of 7.56%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.27 which suggests that it could grow by 59.66%. Given that Intellia Therapeutics, Inc. has higher upside potential than Personalis, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Personalis, Inc..

Personalis, Inc. has a beta of 1.960, which suggesting that the stock is 96.049% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.054, suggesting its more volatile than the S&P 500 by 105.378%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Personalis, Inc.'s net income of -$21.7M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 12.65x versus 25.42x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Biosciences of California, Inc. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -98.85%. Personalis, Inc.'s return on equity of -39.33% beat Pacific Biosciences of California, Inc.'s return on equity of -218.65%.

Personalis, Inc. has a consensus price target of $11.14, signalling upside risk potential of 7.56%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.42 which suggests that it could fall by -4.1%. Given that Personalis, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Personalis, Inc. is more attractive than Pacific Biosciences of California, Inc..

Personalis, Inc. has a beta of 1.960, which suggesting that the stock is 96.049% more volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.200, suggesting its more volatile than the S&P 500 by 120.046%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are smaller than Pacific Biosciences of California, Inc. quarterly revenues of $38.4M. Personalis, Inc.'s net income of -$21.7M is higher than Pacific Biosciences of California, Inc.'s net income of -$38M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 12.65x versus 4.91x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -149.38% compared to Personalis, Inc.'s net margin of -27.41%. Personalis, Inc.'s return on equity of -39.33% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Personalis, Inc. has a consensus price target of $11.14, signalling upside risk potential of 7.56%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $41.50 which suggests that it could fall by -2.26%. Given that Personalis, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Personalis, Inc. is more attractive than Twist Bioscience Corp..

Personalis, Inc. has a beta of 1.960, which suggesting that the stock is 96.049% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.191, suggesting its more volatile than the S&P 500 by 119.099%.

Personalis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Personalis, Inc. quarterly revenues are $14.5M, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Personalis, Inc.'s net income of -$21.7M is higher than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Personalis, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis, Inc. is 12.65x versus 6.78x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.